Liu Y - Search Results

1

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon.

Li H, Liang S, Liu L, Zhou D, Liu Y, Zhang Y, Chen X, Zhang J, Cao Z. Li H, et al. Among authors: liu y, liu l. Front Immunol. 2022 Dec 23;13:1091786. doi: 10.3389/fimmu.2022.1091786. eCollection 2022. Front Immunol. 2022. PMID: 36618361 Free PMC article.

2

Keratin 18 phosphorylation as a progression marker of chronic hepatitis B.

Shi Y, Sun S, Liu Y, Li J, Zhang T, Wu H, Chen X, Chen D, Zhou Y. Shi Y, et al. Among authors: liu y. Virol J. 2010 Mar 24;7:70. doi: 10.1186/1743-422X-7-70. Virol J. 2010. PMID: 20334631 Free PMC article.

3

[Responsive factors and predictors of interferon treatment in patients with chronic hepatitis B].

Liu YL, Chen XY. Liu YL, et al. Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18(6):410-3. doi: 10.3760/cma.j.issn.1007-3418.2010.06.004. Zhonghua Gan Zang Bing Za Zhi. 2010. PMID: 20587308 Chinese. No abstract available.

4

[Higher dose of interferon treatment of chronic hepatitis C patient with primary non-response: a case report].

Liu YL, Chen XY. Liu YL, et al. Zhonghua Gan Zang Bing Za Zhi. 2010 Dec;18(12):950. doi: 10.3760/cma.j.issn.1007-3418.2010.12.020. Zhonghua Gan Zang Bing Za Zhi. 2010. PMID: 21205489 Chinese. No abstract available.

5

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.

Zhang Y, Liu Y, Zhao Y, Shi L, Ma L, Yan H, Wu H, Wei L, Dong T, Chen X. Zhang Y, et al. Among authors: liu y. Liver Int. 2012 Jan;32(1):102-9. doi: 10.1111/j.1478-3231.2011.02652.x. Epub 2011 Sep 26. Liver Int. 2012. PMID: 22098382

6

Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.

Chen X, Cao Z, Liu Y, Zhang H, Zhang Y, Ma L, Jin Y, Yu H, Ma B, Zheng Y, Wu H. Chen X, et al. Among authors: liu y. J Gastroenterol Hepatol. 2012 Mar;27(3):481-6. doi: 10.1111/j.1440-1746.2011.06970.x. J Gastroenterol Hepatol. 2012. PMID: 22098411

7

[The clinical significance of PreS1Ag and anti-PreS1 in patients with chronic hepatitis B].

Zhang XD, Ren S, Yu HB, Liu YL, Jin Y, Huang YX, Chen JM, Chen XY. Zhang XD, et al. Among authors: liu yl. Zhonghua Gan Zang Bing Za Zhi. 2011 Sep;19(9):674-7. doi: 10.3760/cma.j.issn.1007-3418.2011.09.010. Zhonghua Gan Zang Bing Za Zhi. 2011. PMID: 22152382 Chinese.

8

[Efficacy of low-dose interferon therapy for treating chronic hepatitis C patients who cannot tolerate standard treatment].

Cao ZH, Liu YL, Zheng YH, Ji SD, Wang JL, Liao JH, Zhang CY, Chen XY. Cao ZH, et al. Zhonghua Gan Zang Bing Za Zhi. 2012 Jan;20(1):20-4. doi: 10.3760/cma.j.issn.1007-3418.2012.01.008. Zhonghua Gan Zang Bing Za Zhi. 2012. PMID: 22464701 Clinical Trial. Chinese.

9

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.

Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Cao ZH, et al. J Dig Dis. 2013 Aug;14(8):446-50. doi: 10.1111/1751-2980.12065. J Dig Dis. 2013. PMID: 23615131 Clinical Trial.

10

MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B.

Wang S, Zhang X, Ju Y, Zhao B, Yan X, Hu J, Shi L, Yang L, Ma Z, Chen L, Liu Y, Duan Z, Chen X, Meng S. Wang S, et al. Among authors: liu y. J Immunol. 2013 Jul 1;191(1):293-301. doi: 10.4049/jimmunol.1202100. Epub 2013 May 22. J Immunol. 2013. PMID: 23698745

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208,672 results

Search Page

Filters